Exploring DVAI for your organisation? Arrange a confidential, no-obligation discussion. Confidential discussion
Pharma Agents · Cluster 4 of 5

Regulatory & audit readiness

The submission and inspection edge — drafting IMPD modules for human review and mapping cross-system traceability ahead of an MHRA inspection. Read-only, human-signed, audit-trail-safe by design.

Use case 508

IMPD dossier drafting support

The pain point

Assembling the Quality, Non-Clinical and Clinical sections of an Investigational Medicinal Product Dossier for the MHRA means manually consolidating data from hundreds of lab sheets, stability tables and validation logs across different scientific groups — a major, error-prone workload at peak filing times.

Impact — organisation

Regulatory Affairs overloaded during active filings; manual consolidation prone to transcription error; long aggregation timelines delaying submission.

Impact — customer / client

For patients, a slower route to the trials and treatments a filing unlocks.

How it’s addressed

The agent extracts data from diverse internal sources and populates standard, submission-ready draft modules. The draft is exactly that — it must go through full human editing, clinical review and regulatory-operations validation before any submission.

The benefits
Organisation

Designed to reduce the document-aggregation burden at peak filing times, freeing Regulatory Affairs to focus on review and validation — the submission decision and sign-off remaining human.

Customer / client

For patients, a potentially faster time-to-filing, with human review unchanged.

Use case 509

Audit-readiness & traceability mapping

The pain point

Data-integrity lapses dominate MHRA findings — nearly 40% of critical and major GMP deficiencies (2016–2023) related to data integrity, from disabled audit trails to fragmented hybrid systems.55 Tracing a single manufacturing action back to its raw laboratory data ahead of an inspection can take days of manual cross-referencing.

GxP regulatory boundary. Within a GxP environment the MHRA/FDA boundary is absolute: this agent does not create, alter, delete or approve any regulated GxP record, and it gives no clinical or medical advice. It triages, summarises and surfaces information for the review and validated signature of a qualified human (21 CFR Part 11 / EudraLex Annex 11). Every regulated decision, and the integrity of every record, remains with the responsible person.
Impact — organisation

Days of manual cross-referencing before an inspection; data gaps discovered late, if at all; audit-trail and traceability weaknesses that become findings.

Impact — customer / client

For the market, quality and supply risk when traceability cannot be demonstrated.

How it’s addressed

The agent builds a searchable map linking LIMS, MES and batch records, helping QA teams find data gaps before auditors arrive. It is an observation and query tool only — it cannot modify audit trails, overwrite logs or bypass any security control.

The benefits
Organisation

Designed to help QA surface traceability gaps ahead of inspection, on a read-only basis — strengthening audit readiness without ever touching the integrity of the underlying records.

Customer / client

For the market, better-assured product quality and traceability; for inspectors, a more structured review.

Previous cluster Pharmacovigilance & genomics

See how these map onto your organisation. Request a confidential discussion.

Get started
Confidential discussion

Talk to our Customer Success Team.

Take it further with a confidential, no-obligation discussion to scope a pilot in your environment.

Private & no-obligation

Every enquiry is held in confidence. We’ll walk you through the use cases relevant to you and scope how a sovereign deployment would work in your environment — with no obligation to proceed.

Request a meeting with the CST

We aim to respond within one working day.

Held in confidence · no obligation

Sources & references

Statistics describe demand and conditions across the relevant sector and are drawn from the cited public sources. They characterise the sector-level problem these agents address; they are not performance claims for any DVAI product. Deep Voice AI Limited is a pre-revenue company and makes no representation as to outcomes for any individual organisation. Figures are current as at the date of the cited publications.

Capable AI, on your terms — not the cloud’s.

Products
Business Agents
Company
Legal